Back to Search
Start Over
169P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC.
- Source :
-
Annals of Oncology . 2020 Supplement 6, Vol. 31, pS1304-S1305. 2p. - Publication Year :
- 2020
- Subjects :
- *ATEZOLIZUMAB
*HEPATOCELLULAR carcinoma
*ADVERSE health care events
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 31
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152684703
- Full Text :
- https://doi.org/10.1016/j.annonc.2020.10.190